Feed aggregator

Dantari Debuts with $47M to Make Better ADCs

Biospace news - Thu, 12/08/2022 - 02:00
With $47 million in hand, Dantari launched Thursday to advance its Targeted High-capacity Drug Conjugate technology – its take on an antibody-drug conjugate - for solid tumors.

Sanofi Backs Out of Revolution Partnership in Latest Cancer Cull

Biospace news - Thu, 12/08/2022 - 02:00
Sanofi has terminated its global development and commercialization pact with Revolution Medicines, Inc. for their SHP2 inhibitor drug candidate,

Psychedelic Medicine Takes Another Step Forward with Compass’ Twin Updates

Biospace news - Thu, 12/08/2022 - 02:00
Compass' twin clinical updates regarding its lead candidate spotlight the promise of psychedelic medicine.

Instil Bio Trashes a TIL Therapy, Cuts 60% of Staff

Biospace news - Thu, 12/08/2022 - 02:00
Instil Bio is discontinuing the development of its unmodified tumor-infiltrating lymphocyte (TIL) therapeutic, ITIL-168, and laying off 60% of its staff.

How to Cope with Setbacks and Stay Positive in an Unpredictable Industry

Biospace news - Thu, 12/08/2022 - 02:00
Those who work in the biopharma industry often see more setbacks than successes. To understand how to overcome failures, BioSpace spoke with two experts on coping with setbacks and staying positive.

New receptor "decoy" drug neutralizes COVID-19 virus and its variants

World Pharma News - Wed, 12/07/2022 - 11:00
Scientists at Dana-Farber Cancer Institute have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant. The drug is designed in such a way that natural selection to maintain infectiousness of the virus should also maintain the drug’s activity against future variants.

Pfizer and Clear Creek Bio to collaborate on a research program targeting SARS-CoV-2 papain-like protease

World Pharma News - Tue, 12/06/2022 - 11:00
Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19. PLpro is an essential enzyme, which, along with the main protease (Mpro), plays an important role in viral replication.

Mirati's KRAS Inhibitor Demonstrates Encouraging Clinical Profile in Latest Data Drop (Updated)

Biospace news - Tue, 12/06/2022 - 02:00
Mirati's adagrasib demonstrated a solid safety profile in new data released Monday. Despite this, the company's stock fell 8% in after-hours trading.

Editas' Latecomer SCD Therapy Shows Promise in Two Patients

Biospace news - Tue, 12/06/2022 - 02:00
Editas Medicine released positive proof of concept data Tuesday morning from the first patients dosed with its experimental CRISPR-based gene therapy for sickle cell disease.

Entact Bio Draws $81M Financing for Protein Enhancement Platform (Updated)

Biospace news - Tue, 12/06/2022 - 02:00
Entact Bio launched with $81 million Tuesday to advance its protein enhancement platform.

MEI Abandons PI3K Inhibitor, 30% of Staff in Strategic Shift

Biospace news - Tue, 12/06/2022 - 02:00
MEI Pharma, Inc. will have a strategic realignment that would see at least 30% of its workforce laid off and a pivot towards two of its earlier clinical-stage assets.

Progress Flickers in Women’s Healthcare as Femtech Builds Traction

Biospace news - Tue, 12/06/2022 - 02:00
The worldwide market for therapeutics designed specifically for conditions and diseases that affect mainly women is expected to exceed $65 billion by 2027. BioSpace looks at three femtech leaders.

FUJIFILM Diosynth Biotechnologies: There’s a New Cell Therapy Employer in Thousand Oaks

Biospace news - Tue, 12/06/2022 - 02:00
FUJIFILM Diosynth Biotechnologies is offering unique opportunities to join one of the top global CDMOs focused on solving some of the most complex healthcare challenges.

The Top 12 Biopharma Companies Hiring Now

Biospace news - Tue, 12/06/2022 - 02:00
In the past few weeks, the biopharma industry has been filled with layoffs and company launches. To learn about job opportunities at some of the industry's top companies, see inside.

New clue discovered for how and why cancer cells spread

World Pharma News - Mon, 12/05/2022 - 11:00
An international team of researchers has uncovered a new mechanism that enables cancer cells to move throughout the body, providing a potential new target to stop metastasis, which is responsible for 90 per cent of cancer deaths.

In findings published in Nature, the team identifies that cancer cells move faster when they are surrounded by thicker fluids, a change that occurs when lymph drainage is compromised by a primary tumour.

FDA Outlines Path Forward for Verve’s Lead Candidate, VERVE-101

Biospace news - Mon, 12/05/2022 - 02:00
Monday, Verve Therapeutics revealed that the FDA has officially requested several buckets of additional safety information to lift the hold on its lead candidate, VERVE-101.

Janssen Bows Out as Contender for Horizon Therapeutics Buyout

Biospace news - Mon, 12/05/2022 - 02:00
Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday. This leaves Amgen and Sanofi at the bidding table.

Protracted Job Searches Exact Weighty Mental Health Toll

Biospace news - Mon, 12/05/2022 - 02:00
Whether a job search is voluntary or not, months of interviews, wrangling over pay and benefits and evaluating options has a weighty psychological toll.

SonoThera Bags $60M for Ultrasound-Guided, Non-Viral Gene Therapy

Biospace news - Mon, 12/05/2022 - 02:00
​​​​​​​SonoThera closed its Series A round of financing Monday, counting $60.75 million in earnings and will use these proceeds to advance its ultrasound-guided, non-viral gene therapy platform.